Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 9, 2001, Pages 578-581

  Parker, Robert I ^a   Prakash, Devina ^a   Mahan, Rosemary A ^a   Giugliano, Debra M ^a   Atlas, Mark P ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

5 HT blockers; Antiemetic therapy; Intrathecal chemotherapy

Indexed keywords

CYTARABINE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; ONDANSETRON; PLACEBO; PREDNISONE; SODIUM CHLORIDE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; BRAIN LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

6-MERCAPTOPURINE; ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; LEUKEMIA; MALE; METHOTREXATE; NAUSEA; ONDANSETRON; RISK; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VINCRISTINE; VOMITING;

EID: 0035696207     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200112000-00005     Document Type: Article

References (25)

1. Fozard JR. 5-HT3 receptors and cytotoxic drug-induced vomiting. Trends Pharmacol Sci 1987; 8: 44-5.
2. Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810-6.
3. Aapro MS. 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991; 42: 551-68.
4. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18: 163-73.
5. Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of aa 5-HT(3) regimen and literature review. Support Care Cancer 1999; 7: 413-24.
6. Sandoval C, Corbi D, Strobino B, et al. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naïve pediatric oncology patients. Cancer Invest 1999; 17: 309-13.
7. Needles B, Miranda E, Garcia Rodriguez FM, et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. Support Care Cancer 1999; 7: 347-53.
8. Holdsworth MT, Raisch DW, Winter SS, et al. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Support Care Cancer 1998; 6: 132-8.
9. Parker RI, Mahan RA, Giugliano D, et al. Efficacy and safety of intravenous midazolam and ketamine as sedation for therapeutic and diagnostic procedures in children. Pediatrics 1997; 99: 427-31.
10. Figueredo E, Canosa L. Prophylactic ondansetron for postoperative emesis. Meta-analysis of its effectiveness in patients with previous history of postoperative nausea and vomiting. Acta Anaesthesiol Scand 1999; 43: 637-44.
11. Figueredo ED, Canosa LG. Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis. J Clin Anesth 1998; 10: 211-21.
12. Sinha PK, Tripathi M, Ambesh SP. Efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting in patients following infratentorial surgery: a placebo-controlled prospective double-blind study. J Neurosurg Anesthesiol 1999; 11: 6-10.
13. Sadhasivam S, Saxena A, Kathirvel S, et al. The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. Anesth Analg 1999; 89: 1340-5.
14. Gurler T, Celik N, Totan S, et al. Prophylactic use of ondansetron for emesis after craniofacial operations in children. J Craniomaxillofac Surg 1999; 10: 45-8.
15. Goodarzi M. A double-blind comparison of droperidol and ondansetron for prevention of emesis in children undergoing orthopedic surgery. Paediatr Anaesth 1998; 8: 325-9.
16. Pitkanen MT, Numminen MK, Touminen MK, et al. Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine. Eur J Anaesthesiol 1997; 14: 172-7.
17. Mercadante S, Sapio M, Serretta R. Ondansetron in nausea and vomiting induced by spinal morphine. J Pain Symptom Manage 1998; 16: 259-62.
18. Splinter WM, Rhine EJ. Prophylactic antiemetics in children undergoing tonsillectomy: high-dose vs. low-dose ondansetron. Paediatr Anaesth 1997; 7: 125-30.
19. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administration as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969-75.
20. Lawhorn CD, Kymer PJ, Stewart FC, et al. Ondansetron dose response curve in high-risk pediatric patients. J Clin Anesth 1997; 9: 637-42.
21. Ramamoorthy C, Geiduschek JM, Bratton SL, et al. Postdural puncture headache in pediatric oncology patients. Clin Pediatr 1998; 37: 247-51.
22. Burt N, Dorman BH, Reeves ST, et al. Postdural puncture headache in paediatric oncology patients. Can J Anaesth 1998; 45: 741-5.
23. Blaney SM, Poplack DG, Godwin K, et al. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol 1995; 13: 177-9.
24. Wang LP, Schmidt JF. Central nervous side effects after lumbar puncture. A review of the possible pathogenesis of the syndrome of postdural puncture headache and associated symptoms. Dan Med Bull 1997; 44: 79-81.
25. Jacot A, Bissonnette B, Favre JB, et al. The effect of ondansetron on intracranial pressure and cerebral perfusion pressure in neurological patients. Ann Fr Anesth Reanim 1998; 17: 220-6.